Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.
Approval Alert | Three-Month Leuprolide Mesylate Formulation in Advanced Prostate Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
Cevostamab Post-CAR T-Cell Therapy is Safe in Heavily Pretreated Multiple Myeloma
3
BPd Maintenance Safe, Yields Responses in High-Risk Multiple Myeloma
4
Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma
5
